Please call your physician’s office before coming in for your appointment if you have symptoms of a cough, fever, or difficulty breathing; traveled to Europe or China or other areas impacted by the coronavirus (COVID-19) within the past 14 days; been in close contact with someone who has traveled outside the U.S. to one of the impacted countries; or may have been exposed to the coronavirus. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Our new office hours are: Monday through Friday 8:30 a.m. to 4:00 p.m, if you have an appointment scheduled for after hours, our office will be contacting you directly to reschedule. FOR THE LATEST UP TO DATE INFORMATION, ALERTS AND CANCELLATIONS PLEASE CLICK HERE
Neelima Denduluri, MD
My profession and expertise in oncology care affords me a very special and unique opportunity to help alleviate a patient’s stress and uncertainty at a most challenging and vulnerable time in their life. By combining exceptional patient care with the most cutting edge treatments, I am able to tailor each patient’s plan of care specifically to meet their individual needs and concerns.
Dr. Neelima Denduluri earned her medical degree from the Louisiana State University Medical Center, where she served as President of the American Medical Student Association. Upon graduation she received the “Exemplar of Desirable Attitudes of the Physician Towards His Patients” award, which is bestowed upon one graduating senior. She completed her Internal Medicine residency at Georgetown University Medical Center. During her fellowship at the National Cancer Institute, she was honored with the distinction of serving as Chief Fellow. She later served as Assistant Clinical Investigator and Staff Physician at NCI before joining Virginia Cancer Specialists.
Dr. Denduluri remains highly involved in the local community by participating in community outreach, speaking to support groups, and volunteering at the Arlington Free Clinic since 1999. She has consistently been named as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine, and she has been featured in both local and national media for her expertise in breast cancer.
In addition to her passion for patient care, Dr. Denduluri’s dedication to the advancement of medicine has led her to take on multiple leadership roles, including: Associate Chair of the US Oncology Breast Cancer Research Committee; Former Chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Committee and Current Member of the ASCO Education Committee; and Cancer Committee Chairman at Virginia Hospital Center. Dr. Denduluri also currently serves as an associate and principal investigator on many clinical trials, and is a steering committee member for NAPBC accreditation for the Reinsch Pierce Family Center for Breast Health.
Dr. Denduluri continues to be active in medical education, currently serving as Clinical Assistant Professor at Georgetown University Medical Center. She has also taught attending students and residents of Virginia Commonwealth University, as well as oncology fellows at the National Navel Medical Center in Bethesda, MD. Dr. Denduluri has published multiple articles and abstracts, and her work has been presented at various national meetings, including the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium.
Dr. Denduluri is fluent in English, Spanish, and Telugu (an Indian language).
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary.
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
CLEE011O12301C (TRIO033): A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED TRIAL OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN’S CHOICE FOR HER2LOW, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A (TRASTUZUMAB DERUXTECAN), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PRETREATED WITH PRIOR STANDARD OF CARE HER2 THERAPIES, INCLUDING T-DM1